
Siamak Mahmoudiandehkordi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5670787/publications.pdf Version: 2024-02-01



Siamak

#	Article	IF	CITATIONS
1	Serum metabolites associated with brain amyloid beta deposition, cognition and dementia progression. Brain Communications, 2021, 3, fcab139.	1.5	21
2	Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression. Translational Psychiatry, 2021, 11, 153.	2.4	46
3	Bile acid synthesis, modulation, and dementia: A metabolomic, transcriptomic, and pharmacoepidemiologic study. PLoS Medicine, 2021, 18, e1003615.	3.9	38
4	Multi-omics driven predictions of response to acute phase combination antidepressant therapy: a machine learning approach with cross-trial replication. Translational Psychiatry, 2021, 11, 513.	2.4	20
5	Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes. Journal of Affective Disorders, 2020, 264, 90-97.	2.0	36
6	Metabolic Network Analysis Reveals Altered Bile Acid Synthesis and Metabolism in Alzheimer's Disease. Cell Reports Medicine, 2020, 1, 100138.	3.3	102
7	Circulating ethanolamine plasmalogen indices in Alzheimer's disease: Relation to diagnosis, cognition, and CSF tau. Alzheimer's and Dementia, 2020, 16, 1234-1247.	0.4	15
8	Alzheimer's Risk Factors Age, APOE Genotype, and Sex Drive Distinct Molecular Pathways. Neuron, 2020, 106, 727-742.e6.	3.8	152
9	Sex and APOE ε4 genotype modify the Alzheimer's disease serum metabolome. Nature Communications, 2020, 11, 1148.	5.8	115
10	Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers. JAMA Network Open, 2019, 2, e197978.	2.8	142
11	Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients. Translational Psychiatry, 2019, 9, 173.	2.4	53
12	Bile acids targeted metabolomics and medication classification data in the ADNI1 and ADNIGO/2 cohorts. Scientific Data, 2019, 6, 212.	2.4	15
13	Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment. Frontiers in Neuroscience, 2019, 13, 926.	1.4	15
14	Altered bile acid profile associates with cognitive impairment in Alzheimer's disease—An emerging role for gut microbiome. Alzheimer's and Dementia, 2019, 15, 76-92.	0.4	396
15	Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers. Alzheimer's and Dementia, 2019, 15, 232-244.	0.4	198
16	F3â€02â€02: CIRCULATING METABOLITES' ASSOCIATION WITH ALZHEIMER'S DISEASE–ASSOCIATED GEN VARIANTS. Alzheimer's and Dementia, 2018, 14, P997.	ETIC 0.4	0
17	F3â€02â€01: ALTERED BILE ACID METABOLITES IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE: RELATION TO NEUROIMAGING AND CSF BIOMARKERS. Alzheimer's and Dementia, 2018, 14, P997.	0.4	0
18	Metabolic network failures in Alzheimer's disease: A biochemical roadÂmap. Alzheimer's and Dementia, 2017, 13, 965-984.	0.4	362

#	Article	IF	CITATIONS
19	Targeted metabolomics and medication classification data from participants in the ADNI1 cohort. Scientific Data, 2017, 4, 170140.	2.4	49